Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights –Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028. PALO ALTO, Calif.& NEW YORK---- Evommune, Inc., a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the...

#EVMN Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/EVMN/evommune-repor...

Just In: ( NYSE: #EVMN ) EVMN Price Target Alert: $55.00. Issued by Evercore ISI

Just In: ( NYSE: #EVMN ) Buy Recommendation Issued On EVMN By H.C. Wainwright

JUST IN: ( NYSE: #EVMN ) Evommune Stock Skyrockets Following Positive Phase 2a Trial Results for Eczema Drug

📢 Stocks Trending NOW: #SPOT #KO #SPGI #FISV #CVS #TSM #OSCR #DDOG #CRDO #EVMN

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update Evommune (NYSE: EVMN) reported Q3 2025 results and a business update highlighting upcoming clinical milestones and its recent IPO. The company expects three Phase 2 readouts in 2026 across lead programs EVO756 (MRGPRX2 antagonist) and EVO301 (IL-18 inhibitor), including Phase 2b top-line data in CSU in 1H26 and Phase 2a/2b AD readouts in 1H–2H26. The company completed an IPO in November 2025, raising $172.5 million gross proceeds. Q3 financials: $10.0M revenue (collaboration with Maruho), $76.0M cash and investments as of Sept 30, 2025, R&D expense of $19.6M, and net loss of $12.5M.

#EVMN Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/EVMN/evommune-repor...

Breaking News: ( NYSE: #EVMN ) Overweight Recommendation Issued On EVMN By Morgan Stanley

Evommune Successfully Completes Initial Public Offering, Raising $172.5 Million Evommune, a clinical-stage biotech firm, closes its IPO, raising $172.5 million with shares trading on NYSE under the symbol 'EVMN.'

Evommune Successfully Completes Initial Public Offering, Raising $172.5 Million #United_States #Palo_Alto #biotechnology #Evommune #EVMN